Hydroxyurea-induced nail pigmentation in HIV patients.
Hydroxyurea (HU), a cytotoxic agent used in myeloproliferative disorders, has recently been introduced as an adjunct to combination anti-retroviral therapy. We describe abnormal nail pigmentation in four HIV-seropositive patients treated with HU and discuss the likely factors associated with its development.
Joyner
S
S
Department of Genito-urinary Medicine, St George's Hospital, Tooting, London SW17 0QT, UK.
Lee
D
D
Hay
P
P
Lau
R
R
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D044383:Black People; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000627:therapeutic use; D017495:Hyperpigmentation / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009262:Nails / Q000473:pathology*; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019384:Nucleic Acid Synthesis Inhibitors; D006918:Hydroxyurea